Introduction
In the world of medicines, even a small similarity in brand names can create confusion that might affect patient safety. The Delhi High Court recently addressed this concern in a long-running dispute between two pharmaceutical companies. The case involved a well-known heart medicine sold under the name PLAVIX by the French company Sanofi and a similar product marketed as CLAVIX by Intas Pharmaceuticals. The court had to decide whether using a nearly identical name for the same type of drug amounted to trademark infringement and passing off. This judgement highlights how courts carefully examine brand names for medicines to protect both business rights and public health.
Factual Background
Sanofi is a global pharmaceutical company known for developing and selling various medicines, including an important anti-thrombosis drug that helps prevent heart attacks and strokes. This drug is sold under the trademark PLAVIX, a specially created word that does not directly describe the medicine or its use. Sanofi had registered this mark in India and built a significant reputation through sales and promotion over many years. The company launched the product in the Indian market in early 2003.
Intas Pharmaceuticals, an Indian company based in Ahmedabad, began selling a similar medicine containing the same active ingredient under the name CLAVIX. Intas claimed it had started using this name around 2001 and developed its own goodwill in the market. According to Intas, the name CLAVIX was derived from parts of the drug’s scientific name and its medical purpose.
Similarity Of Products And Market
The two products were identical in their therapeutic use and were sold through the same channels, mainly through prescriptions to doctors and pharmacies. Sanofi became aware of Intas’s use of CLAVIX in the mid-2000s and eventually filed a lawsuit, claiming that the similar name was likely to confuse doctors, pharmacists, and patients, leading them to mistake one product for the other.
Key Comparison: PLAVIX Vs CLAVIX
| Factor | PLAVIX (Sanofi) | CLAVIX (Intas) |
|---|---|---|
| Type of Drug | Anti-thrombosis medicine | Same therapeutic use |
| Launch Timeline | Early 2003 (India) | Claimed use since 2001 |
| Trademark Nature | Invented word | Derived from scientific terms |
| Market Channel | Prescription-based | Prescription-based |
Procedural Background
The lawsuit began as a claim for passing off in 2008. Later, after Sanofi’s word mark PLAVIX received formal registration, the company amended its pleadings to also include a claim for trademark infringement. The case went through several procedural steps, including applications for adding documents, recording evidence before a local commissioner, and addressing changes in the plaintiff’s company name from Sanofi Aventis to Sanofi.
Litigation Progress
- Initial passing off claim filed in 2008
- Amendment to include trademark infringement after registration
- Evidence recorded before Local Commissioner
- Corporate name transition from Sanofi Aventis to Sanofi
- Multiple hearings over several years
Both sides presented witnesses and evidence regarding their adoption of the marks, sales, advertising, and reasons for choosing the names. The matter was heard over multiple dates spanning several years, with arguments focusing on the similarity of the marks, the special rules that apply to pharmaceutical products, and whether Intas had honestly adopted its mark or was trying to ride on Sanofi’s reputation. The evidence recording concluded in 2018, and final arguments were completed in March 2026, before the judgement was delivered.
Deceptive Similarity Analysis
The court examined whether the marks PLAVIX and CLAVIX were deceptively similar. It noted that Plavix is a coined word with no direct meaning, making it highly distinctive and deserving of strong protection. The only difference between the two names was the first letter, P versus C. When viewed as a whole, the names looked and sounded very much alike, especially to a person with average memory who might not recall the exact spelling.
Heightened Standard In Pharmaceutical Cases
The court emphasised that medicines require extra caution because any mix-up can harm health. It referred to the well-known principle that in pharmaceutical cases, courts must apply a stricter test for confusion. Even though both drugs required a doctor’s prescription, the possibility of mistakes in reading handwriting, verbal communication, or dispensing errors could not be ignored, particularly in a country with diverse languages and literacy levels.
Defendant’s Explanation For “Clavix”
The judge also considered Intas’s explanation for creating the name CLAVIX. The court found this reasoning unconvincing and it appeared to be an afterthought rather than a genuine and honest choice made independently. Intas had not conducted proper searches before adopting the mark, and it was already selling the same drug under other names, which raised questions about the real motive behind choosing a name so close to PLAVIX.
Limited Role Of Packaging, Colour, Or Price
Differences in packaging, colour, or price were noted but given limited weight in the infringement claim. Once the core names were found deceptively similar, added features in the overall get-up could not fully save the situation in an infringement action. The court clarified the legal position regarding device marks and word marks, holding that the prominent word element in a registered label mark deserves protection.
Section 34 Prior User Defence
The Court also observed that the defendant cannot assert the benefit of prior user in terms of Section 34 of the Act, as such protection is available only to a bona fide adopter and user of the mark. A party who has adopted a mark with knowledge of the plaintiff’s prior rights, or with an intention to ride upon the goodwill and reputation attached thereto, cannot seek refuge under the doctrine of prior use. The statutory defence under Section 34 is not meant to shield acts tainted with bad faith or to legitimise an attempt to cause confusion or deception in the market. Consequently, the defendant is disentitled from claiming any protection on the ground of prior user, and the said plea is liable to be rejected.
Key Takeaways
- Coined and distinctive marks receive strong legal protection.
- Pharmaceutical trademarks are judged under a stricter confusion test.
- Minor differences (such as a single letter) may still result in infringement.
- Packaging or pricing differences cannot override deceptive similarity.
- Prior user defence under Section 34 requires bona fide adoption.
Quick Comparison: PLAVIX vs CLAVIX
| Criteria | PLAVIX | CLAVIX |
|---|---|---|
| Nature of Mark | Coined, highly distinctive | Similar constructed word |
| Visual Similarity | High (difference only in first letter) | |
| Phonetic Similarity | High (similar pronunciation) | |
| Likelihood of Confusion | Significant, especially in pharmaceutical context | |
| Legal Outcome | Protected | Infringing |
Judgements With Complete Citation And Their Context Discussed
The court relied on several important precedents to guide its decision. A central reference was the Supreme Court case Cadila Health Care Ltd. Vs. Cadila Pharmaceuticals Ltd (2001) 5 SCC OnLine SC 578.
Cadila Health Care Ltd. Vs. Cadila Pharmaceuticals Ltd (2001)
In that matter, the Supreme Court stressed that disputes involving medicinal products demand a stricter approach because confusion between drugs can have serious, even life-threatening, consequences.
- Medicines are not ordinary consumer goods
- Illiteracy increases the likelihood of confusion
- Linguistic diversity contributes to misunderstanding
- Hospital pressure situations increase risk of error
This principle was applied directly here to evaluate the likelihood of confusion between PLAVIX and CLAVIX.
Kaviraj Pandit Durga Dutt Sharma Vs Navaratna Pharmaceutical Laboratories (1964)
Another key authority was Kaviraj Pandit Durga Dutt Sharma Vs Navaratna Pharmaceutical Laboratories (1964) SCC OnLine SC 14, where the Supreme Court explained the difference between trademark infringement and passing off actions.
| Aspect | Trademark Infringement | Passing Off |
|---|---|---|
| Focus | Essential Features Of Registered Mark | Overall Presentation (Get-Up, Packaging) |
| Importance Of Differences | Less Significant If Core Features Are Copied | More Significant In Determining Deception |
It clarified that in infringement cases, if the essential features of the registered mark are copied, differences in get-up or packaging may not matter much, unlike in pure passing-off claims.
Corn Products Refining Co. Vs. Shangrila Food Products Ltd (1959)
The court also discussed Corn Products Refining Co. Vs. Shangrila Food Products Ltd (1959) SCC OnLine SC 11, which laid down that marks must be compared as a whole from the perspective of an ordinary buyer with imperfect recollection.
- Comparison must be holistic, not dissected
- Perspective of average consumer is key
- Imperfect recollection is assumed
Other cases cited helped distinguish situations where common elements derived from generic or scientific names were involved, showing why those precedents did not help Intas in this instance.
Recent Delhi High Court Decisions
Recent Delhi High Court decisions were referred to on issues such as the protection of essential word features in composite or device marks and the limited role of manufacturer names or additional elements when the marks themselves are confusingly similar.
Final Decision Of The Court
After carefully weighing all arguments and evidence, the Delhi High Court decided the case in favour of Sanofi. It held that Intas’s use of the mark CLAVIX constituted trademark infringement of Sanofi’s PLAVIX mark. However, relief of passing off was declined as the plaintiff failed to prove any goodwill and reputation in India. The court found the marks deceptively similar and likely to cause confusion among the trade and public, particularly in the sensitive field of pharmaceuticals. Consequently, the court granted a permanent injunction restraining Intas from manufacturing, selling, or offering for sale any medicinal preparations under the mark CLAVIX or any other deceptively similar mark. Other reliefs, including directions regarding delivery up of materials and consideration of damages or accounts of profits along with costs, followed in line with the findings on the issues framed.
Key Outcomes And Reliefs Granted
- Trademark infringement established in favour of Sanofi.
- Passing off relief denied due to lack of proven goodwill in India.
- Marks held deceptively similar with likelihood of confusion.
- Permanent injunction granted against use of CLAVIX or similar marks.
- Additional reliefs: delivery up, damages/accounts of profits, and costs.
Point Of Law Settled In The Case
This judgement reinforces that in trademark disputes involving pharmaceutical products, courts will apply a stricter standard while assessing deceptive similarity. Even a minor change, such as replacing one letter in a coined mark for identical drugs, can amount to infringement if it creates a likelihood of confusion. The decision also clarifies that packaging differences or the prescription-only nature of drugs do not automatically eliminate the risk of confusion in India’s context.
It further settles that the essential word element in a registered device mark receives protection, and explanations for adopting similar names are scrutinised closely for honesty and independence. The defendant is not entitled to the benefit of prior user under Section 34 of the Act, as the adoption of the impugned mark is found to be dishonest and thus vitiates any claim of bona fide use. Overall, it strengthens the protection available to established pharma trademarks against close imitations that could endanger public health.
Legal Principles Established
- Stricter test for deceptive similarity in pharmaceutical trademarks.
- Minor variations in coined marks can still constitute infringement.
- Packaging and prescription status do not negate confusion risk.
- Word elements in device marks receive strong protection.
- Dishonest adoption defeats prior user defence under Section 34.
Case Details
| Particulars | Details |
|---|---|
| Case Title | Sanofi Vs Intas Pharmaceuticals Ltd & Anr. |
| Date Of Order | 28th April, 2026 |
| Case Number | CS(COMM) 120/2016 |
| Neutral Citation | 2026:DHC:3574 |
| Name Of Court | High Court Of Delhi |
| Name Of Hon’ble Judge | Hon’ble Mr Justice Amit Bansal |
Disclaimer: Readers are advised not to treat this as substitute for legal advise as it may contain errors in perception, interpretation, and presentation.
Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
